What patients can teach us about cancer

2026-10-13T16:35:42+01:0013 October 2026|

Clinician scientist Dr Ayesha Noorani spends her weeks seeing patients, performing complex cancer surgery and connecting the dots through her research at the Wellcome Sanger Institute. She shares how working across both sides of medicine shapes the questions she asks, strengthens her curiosity and drives her research.

What is laser capture microdissection?

2026-09-22T09:13:07+01:0022 September 2026|

We take an inside look into what laser capture microdissection is and how it is enabling scientists at the Wellcome Sanger Institute to precisely isolate cells and reveal detailed insights into biology and disease.

5 questions on CRISPR-Cas with Sandeep Rajan

2026-09-01T08:46:22+01:001 September 2026|

From bacterial defence to breakthrough therapies, we explore how CRISPR-Cas is transforming research and healthcare, and how experts at the Wellcome Sanger Institute are refining the technology to make genome editing more scalable and effective.

One gene, many outcomes: Understanding variable cancer risk in PTEN hamartoma tumour syndrome

2026-08-24T09:30:48+01:0025 August 2026|

Changes in the PTEN gene, that causes PTEN hamartoma tumour syndrome (PHTS), can lead to a range of different manifestations that vary from person to person, including an increased risk of certain cancers. A new project aims to understand why some tissues in people with PHTS become cancerous, and if there is a way of identifying individuals with PTEN variants who are most at risk.

A living library: Inside our organoid biobank

2026-08-05T16:12:36+01:005 August 2026|

Tiny organs, big story. We explore how our organoid biobank came to life – from building long-lived models to making data openly available to the research community.

From bases to breakthroughs: Editing cancer’s weak spots with CRISPR

2026-05-26T13:53:09+01:0026 May 2026|

In the latest installment of our innovator blog series, we caught up with Dr Matthew Coelho, Cancer Research UK Career Development Fellow at the Wellcome Sanger Institute. Matthew works within the Somatic Genomics programme and is co-founder of BASE Rx alongside Group Leader, Dr Mathew Garnett.

What are somatic mutations?

2026-01-15T11:52:25+00:0015 January 2026|

When most people think about genetic changes, or mutations, they imagine inherited conditions that are passed on from parents to offspring. However, the vast majority of mutations in our DNA are not inherited at all. Instead, they arise quietly, cell-by-cell throughout our lifetime. These are somatic mutations, and they are one of the most important – yet least understood – forces acting inside our bodies.

How can we avoid cancer?

2025-11-28T15:34:02+00:0028 November 2025|

Imagine if our bodies held secret playbooks for stopping cancer before it ever gains ground. A new international research team – led by scientists at the Wellcome Sanger Institute – is setting out to uncover exactly those natural defence mechanisms. Their ambitious Cancer Avoidance project hopes to reveal insights that could one day help us halt cancer in its tracks.